Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer

<p><i>PDAC patients expressing DCLK1 demonstrate PI3K/AKT/MTOR pathway activation</i>. RNA-Seq expression data from TCGA PAAD were analyzed. Patients were grouped based on DCLK1 expression and compared expression of genes downstream of RAS activation, grouped into EMT, PI3K/AKT/MTOR, and BCL2/Apoptosis.</p>

Journal of Oncology

fig3

Figure 3

Figure 3: Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer 

Figure 3 | Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer 